Nucleai, a Chicago, IL- and Tel Aviv, Israel-based spatial AI biomarker company, raised $14M in funding.
The round was led by M Ventures, and supported by existing investors.
The company intends to use the funds to accelerate the deployment of its spatial analysis technology.
Led by CEO Avi Veidman, Nucleai is an AI-powered spatial biomarker company, driving innovation at the intersection of technology and healthcare. Leveraging military intelligence-grade geospatial analytical methods, it intercepts, interprets, and analyzes complex cellular conversations and spatially oriented interactions within tissue samples, translating them into actionable insights. Its platform empowers pathologists and researchers with an AI-powered data-rich action plan, enabling them to make informed decisions in the development of bi-specifics, antibody-drug conjugates (ADCs), and immunotherapy.
FinSMEs
03/04/2024